Review



s100a12 primary antibody  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Novus Biologicals s100a12 primary antibody
    FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 <t>(S100A12)</t> in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)
    S100a12 Primary Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a12+primary+antibody/pm23321181-53-34-37?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    s100a12 primary antibody - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Identification of osteoarthritis biomarkers by proteomic analysis of synovial fluid."

    Article Title: Identification of osteoarthritis biomarkers by proteomic analysis of synovial fluid.

    Journal: The Journal of international medical research

    doi: 10.1177/030006051204000622

    FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 (S100A12) in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)
    Figure Legend Snippet: FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 (S100A12) in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)

    Techniques Used: Western Blot, Binding Assay



    Similar Products

    primary antibody s100a12  (Proteintech)
    90
    Proteintech primary antibody s100a12
    Primary Antibody S100a12, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a12+primary+antibody/pm38492210-69-1-3?v=Proteintech
    Average 90 stars, based on 1 article reviews
    primary antibody s100a12 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    s100a12 primary antibody  (Millipore)
    90
    Millipore s100a12 primary antibody
    (A) Heat map of <t>S100A12</t> as most significantly regulated gene in risk groups. The gene and samples are clustered using Centroid linkage and Euclidean distance metric by ArrayStar software. The diagram row represents the S100A12 gene and the risk groups are presented in the columns. Color saturation reflects the differences in gene expression between tumor samples; red is higher than control group expression (blue). The intensity of color indicates the degree of gene expression from red (high expression fold) to yellow (low fold expression). qPCR validation of expression was done for selected genes. Normalized ratio ± ratio error determined for cDNA pools of study risk (B) and prognostic groups (C) by calculation of the ratio of the samples (target/reference) divided by the ratio of run calibrator (target/reference) (healthy samples). Quantitative PCR was performed for S100A12 (black), S100A8 (gray), NAMPT (light gray), JUP (red), KLRF1 (blue), and PTGDR (green). New positive, New UCB cases; recurrent, Cases with recurrence of the disease within 5 years after treatment; previously positive, Cases with UCB history but negative at the time the sample. *** p ≤ 0.0001 and ** p ≤ 0.01.
    S100a12 Primary Antibody, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a12+primary+antibody/pmc06962349-157-5-8?v=Millipore
    Average 90 stars, based on 1 article reviews
    s100a12 primary antibody - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    primary rabbit polyclonal antibody to s100a12  (Danaher Inc)
    99
    Danaher Inc primary rabbit polyclonal antibody to s100a12
    (A) Heat map of <t>S100A12</t> as most significantly regulated gene in risk groups. The gene and samples are clustered using Centroid linkage and Euclidean distance metric by ArrayStar software. The diagram row represents the S100A12 gene and the risk groups are presented in the columns. Color saturation reflects the differences in gene expression between tumor samples; red is higher than control group expression (blue). The intensity of color indicates the degree of gene expression from red (high expression fold) to yellow (low fold expression). qPCR validation of expression was done for selected genes. Normalized ratio ± ratio error determined for cDNA pools of study risk (B) and prognostic groups (C) by calculation of the ratio of the samples (target/reference) divided by the ratio of run calibrator (target/reference) (healthy samples). Quantitative PCR was performed for S100A12 (black), S100A8 (gray), NAMPT (light gray), JUP (red), KLRF1 (blue), and PTGDR (green). New positive, New UCB cases; recurrent, Cases with recurrence of the disease within 5 years after treatment; previously positive, Cases with UCB history but negative at the time the sample. *** p ≤ 0.0001 and ** p ≤ 0.01.
    Primary Rabbit Polyclonal Antibody To S100a12, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a12+primary+antibody/pmc04468547-152-0-7?v=Danaher+Inc
    Average 99 stars, based on 1 article reviews
    primary rabbit polyclonal antibody to s100a12 - by Bioz Stars, 2026-07
    99/100 stars
    		  Buy from Supplier
    s100a12 primary antibody  (Novus Biologicals)
    90
    Novus Biologicals s100a12 primary antibody
    FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 <t>(S100A12)</t> in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)
    S100a12 Primary Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a12+primary+antibody/pm23321181-53-34-37?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    s100a12 primary antibody - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    mouse-antihuman s100a12 primary antibody  (Novus Biologicals)
    90
    Novus Biologicals mouse-antihuman s100a12 primary antibody
    FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 <t>(S100A12)</t> in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)
    Mouse Antihuman S100a12 Primary Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s100a12+primary+antibody/pm23321181-53-33-37?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    mouse-antihuman s100a12 primary antibody - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Heat map of S100A12 as most significantly regulated gene in risk groups. The gene and samples are clustered using Centroid linkage and Euclidean distance metric by ArrayStar software. The diagram row represents the S100A12 gene and the risk groups are presented in the columns. Color saturation reflects the differences in gene expression between tumor samples; red is higher than control group expression (blue). The intensity of color indicates the degree of gene expression from red (high expression fold) to yellow (low fold expression). qPCR validation of expression was done for selected genes. Normalized ratio ± ratio error determined for cDNA pools of study risk (B) and prognostic groups (C) by calculation of the ratio of the samples (target/reference) divided by the ratio of run calibrator (target/reference) (healthy samples). Quantitative PCR was performed for S100A12 (black), S100A8 (gray), NAMPT (light gray), JUP (red), KLRF1 (blue), and PTGDR (green). New positive, New UCB cases; recurrent, Cases with recurrence of the disease within 5 years after treatment; previously positive, Cases with UCB history but negative at the time the sample. *** p ≤ 0.0001 and ** p ≤ 0.01.

    Journal: Frontiers in Oncology

    Article Title: A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection

    doi: 10.3389/fonc.2019.01484

    Figure Lengend Snippet: (A) Heat map of S100A12 as most significantly regulated gene in risk groups. The gene and samples are clustered using Centroid linkage and Euclidean distance metric by ArrayStar software. The diagram row represents the S100A12 gene and the risk groups are presented in the columns. Color saturation reflects the differences in gene expression between tumor samples; red is higher than control group expression (blue). The intensity of color indicates the degree of gene expression from red (high expression fold) to yellow (low fold expression). qPCR validation of expression was done for selected genes. Normalized ratio ± ratio error determined for cDNA pools of study risk (B) and prognostic groups (C) by calculation of the ratio of the samples (target/reference) divided by the ratio of run calibrator (target/reference) (healthy samples). Quantitative PCR was performed for S100A12 (black), S100A8 (gray), NAMPT (light gray), JUP (red), KLRF1 (blue), and PTGDR (green). New positive, New UCB cases; recurrent, Cases with recurrence of the disease within 5 years after treatment; previously positive, Cases with UCB history but negative at the time the sample. *** p ≤ 0.0001 and ** p ≤ 0.01.

    Article Snippet: Sections were incubated with 1:1,000 S100A12 primary antibody (Sigma HPA002881) or PBS/0.1% BSA (negative control), before adding universal secondary antibody (Vector Laboratories, UK).

    Techniques: Software, Expressing, Real-time Polymerase Chain Reaction

    Representative immunohistochemical analysis for tumors of T1, T2, and T3. IHC staining patterns for S100A12 in cancer tissue array tumors stained withanti-S100A12.

    Journal: Frontiers in Oncology

    Article Title: A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection

    doi: 10.3389/fonc.2019.01484

    Figure Lengend Snippet: Representative immunohistochemical analysis for tumors of T1, T2, and T3. IHC staining patterns for S100A12 in cancer tissue array tumors stained withanti-S100A12.

    Article Snippet: Sections were incubated with 1:1,000 S100A12 primary antibody (Sigma HPA002881) or PBS/0.1% BSA (negative control), before adding universal secondary antibody (Vector Laboratories, UK).

    Techniques: Immunohistochemical staining, Immunohistochemistry, Staining

    Quantitation of S100A12 in UCB plasma samples by BLI (A) . The concentration of S100A12 was measured from plasma samples of each group (UCB patients and Healthy) using the biolayer interferometry (BLI). For each group, the mean value for of S100A12 is shown and standard error of the mean is represented by error bars. (B) A ROC analysis of plasma S100A12 concentrations in all UCB patients vs. all healthy in study cohort *** p ≤ 0.0001.

    Journal: Frontiers in Oncology

    Article Title: A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection

    doi: 10.3389/fonc.2019.01484

    Figure Lengend Snippet: Quantitation of S100A12 in UCB plasma samples by BLI (A) . The concentration of S100A12 was measured from plasma samples of each group (UCB patients and Healthy) using the biolayer interferometry (BLI). For each group, the mean value for of S100A12 is shown and standard error of the mean is represented by error bars. (B) A ROC analysis of plasma S100A12 concentrations in all UCB patients vs. all healthy in study cohort *** p ≤ 0.0001.

    Article Snippet: Sections were incubated with 1:1,000 S100A12 primary antibody (Sigma HPA002881) or PBS/0.1% BSA (negative control), before adding universal secondary antibody (Vector Laboratories, UK).

    Techniques: Quantitation Assay, Concentration Assay

    A comparison of S100A12 concentrations in plasma within risk groups. (A) Comparison of plasma concentrations of S100A12 in UCB patients divided into groups according to their risk score. The standard error of the mean is represented by error bars. (B) A ROC analysis of plasma S100A12 concentrations in high risk UCB patients vs. healthy group. (C) A ROC analysis of plasma S100A12 concentrations of intermediate risk UCB patients against study healthy. ns, not significant, *** p ≤ 0.0001 and * p ≤ 0.05.

    Journal: Frontiers in Oncology

    Article Title: A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection

    doi: 10.3389/fonc.2019.01484

    Figure Lengend Snippet: A comparison of S100A12 concentrations in plasma within risk groups. (A) Comparison of plasma concentrations of S100A12 in UCB patients divided into groups according to their risk score. The standard error of the mean is represented by error bars. (B) A ROC analysis of plasma S100A12 concentrations in high risk UCB patients vs. healthy group. (C) A ROC analysis of plasma S100A12 concentrations of intermediate risk UCB patients against study healthy. ns, not significant, *** p ≤ 0.0001 and * p ≤ 0.05.

    Article Snippet: Sections were incubated with 1:1,000 S100A12 primary antibody (Sigma HPA002881) or PBS/0.1% BSA (negative control), before adding universal secondary antibody (Vector Laboratories, UK).

    Techniques:

    Comparison of S100A12 levels in UCB patient prognostics groups. (A) S100A12 concentrations in plasma from UCB patients sorted according to their prognosis. The standard error of the mean is represented by error bars. (B) The ROC analysis of plasma S100A12 concentrations of recurrent group against new positive group of patients. The AUC is 0.793 with standard error 0.09, p = 0.019 and the 95% confidence interval appeared to be 0.6114–0.9759. The best cut-off in this comparison was found to be 512.5 ng/mL, giving 71.4% sensitivity and 66.67% specificity. (C) A ROC analysis of S100A12 concentration of previously positive group (recurrent-negative at sample) compared to new positive group. The AUC is 0.725 with standard error 0.095, p = 0.058 and 95% confidence interval between 0.5387 and 0.911. Using the cut-off 462.5 ng/mL the sensitivity is 68.4% and specificity will be 55.56%. (D) ROC analysis of S100A12 of new positive UCB patients against all healthy. ns, not significant, ** p ≤ 0.01 and * p ≤ 0.05.

    Journal: Frontiers in Oncology

    Article Title: A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection

    doi: 10.3389/fonc.2019.01484

    Figure Lengend Snippet: Comparison of S100A12 levels in UCB patient prognostics groups. (A) S100A12 concentrations in plasma from UCB patients sorted according to their prognosis. The standard error of the mean is represented by error bars. (B) The ROC analysis of plasma S100A12 concentrations of recurrent group against new positive group of patients. The AUC is 0.793 with standard error 0.09, p = 0.019 and the 95% confidence interval appeared to be 0.6114–0.9759. The best cut-off in this comparison was found to be 512.5 ng/mL, giving 71.4% sensitivity and 66.67% specificity. (C) A ROC analysis of S100A12 concentration of previously positive group (recurrent-negative at sample) compared to new positive group. The AUC is 0.725 with standard error 0.095, p = 0.058 and 95% confidence interval between 0.5387 and 0.911. Using the cut-off 462.5 ng/mL the sensitivity is 68.4% and specificity will be 55.56%. (D) ROC analysis of S100A12 of new positive UCB patients against all healthy. ns, not significant, ** p ≤ 0.01 and * p ≤ 0.05.

    Article Snippet: Sections were incubated with 1:1,000 S100A12 primary antibody (Sigma HPA002881) or PBS/0.1% BSA (negative control), before adding universal secondary antibody (Vector Laboratories, UK).

    Techniques: Concentration Assay

    FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 (S100A12) in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)

    Journal: The Journal of international medical research

    Article Title: Identification of osteoarthritis biomarkers by proteomic analysis of synovial fluid.

    doi: 10.1177/030006051204000622

    Figure Lengend Snippet: FIGURE 2: Western blotting analysis for S100 calcium binding protein A12 (S100A12) in synovial fluid from patients with osteoarthritis (A,B) or rheumatoid arthritis (C,D)

    Article Snippet: Molecular weight and electric charge data for potential biomarker peaks were used to identify proteins via the SWISS-PROT database (http://www.uniprot.org/).19 Western blotting of pooled synovial fluid samples was performed as described previously,20,21 using mouse-antihuman S100A12 primary antibody (Novus Biologicals, Littleton, CO, USA) and rabbit antimouse secondary antibody.

    Techniques: Western Blot, Binding Assay